FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response: 0.5

	Check this box if no longer subject
٦	to Section 16. Form 4 or Form 5
╝	obligations may continue. See
	Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Vukovic Vojo  (Last) (First) (Middle)  C/O SYNTA PHARMACEUTICALS CORP.  45 HARTWELL AVENUE						2. Issuer Name and Ticker or Trading Symbol SYNTA PHARMACEUTICALS CORP [ SNTA ]  3. Date of Earliest Transaction (Month/Day/Year) 03/01/2010  4. If Amendment, Date of Original Filed (Month/Day/Year)									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below) below)  SVP, Chief Medical Officer  6. Individual or Joint/Group Filing (Check Applicable)				wner specify
(Street) LEXINGTON MA 02421  (City) (State) (Zip)															X Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day						on 2A. Deemed Execution Date,				3. Transaction Code (Instr. 8)  4. Securitie Disposed Code (5)			quired	I (A) o	or 5. Amount of		Forr (D) d Indi	wnership m: Direct or rect (I) tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
										v	Amoun	nt (A) or (D)		Price	Report Transa			ur. 4)	(mstr. 4)
Common Stock 03/01/20							010		A		7,47	7,477(1)		<b>\$0</b> (1	14,107			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ive Conversion Date y or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		on of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		∵. 3	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership		
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	or	ount nber res					
Employee Stock Option (Right to Buy)	\$4.02	03/01/2010			A		69,420		(2)	03.	/01/2020	Commo	69,	420	\$0	69,420		D	

## Explanation of Responses:

- 1. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 100% of the shares on March 1, 2011, provided the Reporting Person remains employed by the Issuer on such date.
- 2. The option vests as to 25% of the shares on March 1, 2011 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.

/s/ Ann Margaret Eames, Attorney-in-Fact

03/03/2010

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.